229 related articles for article (PubMed ID: 36291832)
1. Quantum Dot-Based Screening Identifies F3 Peptide and Reveals Cell Surface Nucleolin as a Therapeutic Target for Rhabdomyosarcoma.
Dzhumashev D; Timpanaro A; Ali S; De Micheli AJ; Mamchaoui K; Cascone I; Rössler J; Bernasconi M
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291832
[TBL] [Abstract][Full Text] [Related]
2. Rapid liposomal formulation for nucleolin targeting to rhabdomyosarcoma cells.
Dzhumashev D; Anton-Joseph S; Morel VJ; Timpanaro A; Bordon G; Piccand C; Aleandri S; Luciani P; Rössler J; Bernasconi M
Eur J Pharm Biopharm; 2024 Jan; 194():49-61. PubMed ID: 38029941
[TBL] [Abstract][Full Text] [Related]
3. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
Mosafer J; Mokhtarzadeh A
Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of an
Lam PY; Hillyar CR; Able S; Vallis KA
J Labelled Comp Radiopharm; 2016 Oct; 59(12):492-499. PubMed ID: 27594091
[TBL] [Abstract][Full Text] [Related]
5. Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model.
Hajdin K; D'Alessandro V; Niggli FK; Schäfer BW; Bernasconi M
PLoS One; 2010 May; 5(5):e10445. PubMed ID: 20454619
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy of human glioblastoma via delivery of a toxin through a peptide directed to cell surface nucleolin.
Dhez AC; Benedetti E; Antonosante A; Panella G; Ranieri B; Florio TM; Cristiano L; Angelucci F; Giansanti F; Di Leandro L; d'Angelo M; Melone M; De Cola A; Federici L; Galzio R; Cascone I; Raineri F; Cimini A; Courty J; Giordano A; Ippoliti R
J Cell Physiol; 2018 May; 233(5):4091-4105. PubMed ID: 28941284
[TBL] [Abstract][Full Text] [Related]
7. Modelling the impact of nucleolin expression level on the activity of F3 peptide-targeted pH-sensitive pegylated liposomes containing doxorubicin.
Lopes R; Shi K; Fonseca NA; Gama A; Ramalho JS; Almeida L; Moura V; Simões S; Tidor B; Moreira JN
Drug Deliv Transl Res; 2022 Mar; 12(3):629-646. PubMed ID: 33860446
[TBL] [Abstract][Full Text] [Related]
8. Cell surface nucleolin as active bait for nanomedicine in cancer therapy: a promising option.
Ferrara B; Belbekhouche S; Habert D; Houppe C; Vallée B; Bourgoin-Voillard S; Cohen JL; Cascone I; Courty J
Nanotechnology; 2021 May; 32(32):. PubMed ID: 33892482
[TBL] [Abstract][Full Text] [Related]
9. Click conjugation of peptide to hydrogel nanoparticles for tumor-targeted drug delivery.
Qin M; Zong H; Kopelman R
Biomacromolecules; 2014 Oct; 15(10):3728-34. PubMed ID: 25162488
[TBL] [Abstract][Full Text] [Related]
10. Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells.
Pesarrodona M; Sánchez-García L; Seras-Franzoso J; Sánchez-Chardi A; Baltá-Foix R; Cámara-Sánchez P; Gener P; Jara JJ; Pulido D; Serna N; Schwartz S; Royo M; Villaverde A; Abasolo I; Vazquez E
ACS Appl Mater Interfaces; 2020 Feb; 12(5):5381-5388. PubMed ID: 31840972
[TBL] [Abstract][Full Text] [Related]
11. Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphatic-homing peptide LyP-1.
Witt H; Hajdin K; Iljin K; Greiner O; Niggli FK; Schäfer BW; Bernasconi M
Int J Cancer; 2009 May; 124(9):2026-32. PubMed ID: 19123480
[TBL] [Abstract][Full Text] [Related]
12. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels.
Christian S; Pilch J; Akerman ME; Porkka K; Laakkonen P; Ruoslahti E
J Cell Biol; 2003 Nov; 163(4):871-8. PubMed ID: 14638862
[TBL] [Abstract][Full Text] [Related]
13. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery.
Hu Q; Gu G; Liu Z; Jiang M; Kang T; Miao D; Tu Y; Pang Z; Song Q; Yao L; Xia H; Chen H; Jiang X; Gao X; Chen J
Biomaterials; 2013 Jan; 34(4):1135-45. PubMed ID: 23146434
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of somatostatin and nucleolin receptors for therapeutic delivery in non-small cell lung cancer stem cells applying the somatostatin-analog DOTATATE and the nucleolin-targeting aptamer AS1411.
Holmboe S; Hansen PL; Thisgaard H; Block I; Müller C; Langkjær N; Høilund-Carlsen PF; Olsen BB; Mollenhauer J
PLoS One; 2017; 12(5):e0178286. PubMed ID: 28542563
[TBL] [Abstract][Full Text] [Related]
15. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
[TBL] [Abstract][Full Text] [Related]
16. Myogenetic Oligodeoxynucleotides as Anti-Nucleolin Aptamers Inhibit the Growth of Embryonal Rhabdomyosarcoma Cells.
Nohira N; Shinji S; Nakamura S; Nihashi Y; Shimosato T; Takaya T
Biomedicines; 2022 Oct; 10(11):. PubMed ID: 36359210
[TBL] [Abstract][Full Text] [Related]
17. A positron emission tomography image-guidable unimolecular micelle nanoplatform for cancer theranostic applications.
Yang J; Lu W; Xiao J; Zong Q; Xu H; Yin Y; Hong H; Xu W
Acta Biomater; 2018 Oct; 79():306-316. PubMed ID: 30172067
[TBL] [Abstract][Full Text] [Related]
18. Anti-nucleolin aptamer AS1411: an advancing therapeutic.
Van den Avont A; Sharma-Walia N
Front Mol Biosci; 2023; 10():1217769. PubMed ID: 37808518
[TBL] [Abstract][Full Text] [Related]
19. Prolonged circulation and increased tumor accumulation of liposomal vincristine in a mouse model of rhabdomyosarcoma.
Roveri M; Pfohl A; Jaaks P; Alijaj N; Leroux JC; Luciani P; Bernasconi M
Nanomedicine (Lond); 2017 May; 12(10):1135-1151. PubMed ID: 28447920
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
